PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2021.2052022542469-477Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast CancerHyehyun Jeong, Jae Ho Jeong, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Sung-Bae Kimhttp://e-crt.org/upload/pdf/crt-2021-205.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2021.205, http://e-crt.org/upload/pdf/crt-2021-205.pdf
Annals of Oncology10.1016/j.annonc.2021.03.133202132S72-S73119P Clinical efficacy of everolimus and CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer by treatment sequenceJ.H. Jeong, H. Jeong, J.E. Kim, J-H. Ahn, K.H. Jung, S-B. Kimhttps://api.elsevier.com/content/article/PII:S0923753421010115?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753421010115?httpAccept=text/plain
Drug Design, Development and Therapy10.2147/dddt.s3567572022Volume 16727-735Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant SettingHikmat Abdel-Razeq, Baha' Sharafhttps://www.dovepress.com/getfile.php?fileID=79139, https://www.dovepress.com/getfile.php?fileID=79139
Value in Health10.1016/j.jval.2013.08.4212013167A396Comparison Between Everolimus (Afinitor®) and Chemotherapy Agents (Capecitabine, Docetaxel and Doxorubicin) for the Treatment of Hormone Receptor Positive (HR+) HER2 Negative (HER2–) Advanced or Metastatic Breast CancerJ. Vieira, D. Chandiwana, M. Taylor, L. Lewishttps://api.elsevier.com/content/article/PII:S1098301513023267?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1098301513023267?httpAccept=text/plain
Value in Health10.1016/j.jval.2013.08.4092013167A393-A394An Indirect Treatment Comparison of the Efficacy of Everolimus (Afinitor®) and Fulvestrant for the Treatment of Hormone Receptor Positive (HR+) HER2 Negative (HER2–) Advanced or Metastatic Breast CancerD. Chandiwana, J. Vieira, J. Granville, R. McCool, K. Fleetwoodhttps://api.elsevier.com/content/article/PII:S1098301513023140?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1098301513023140?httpAccept=text/plain
Breast Cancer Research10.1186/s13058-021-01394-y2021231Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapyMariya Rozenblit, Sophia Mun, Pamela Soulos, Kerin Adelson, Lajos Pusztai, Sarah Mougalianhttp://link.springer.com/content/pdf/10.1186/s13058-021-01394-y.pdf, http://link.springer.com/article/10.1186/s13058-021-01394-y/fulltext.html, http://link.springer.com/content/pdf/10.1186/s13058-021-01394-y.pdf
Breast Cancer and Surgery10.5772/intechopen.765782018Adjuvant Systemic Treatment in Hormone Receptor Positive, HER2 Negative Breast CancerFatma Senhttp://www.intechopen.com/download/pdf/61285
Asia-Pacific Journal of Clinical Oncology10.1111/ajco.130642018143-11Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigmFrances Boyle, Jane Beith, Katie Burslem, Richard de Boer, Rina Hui, Elgene Lim, Nicole McCarthy, Andrew Redfern, Natasha Woodwardhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fajco.13064, http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajco.13064/fullpdf
OncoTargets and Therapy10.2147/ott.s2987202021Volume 142929-2939Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment with CDK4/6 InhibitorsChao Li, Xujun Lihttps://www.dovepress.com/getfile.php?fileID=69030, https://www.dovepress.com/getfile.php?fileID=69030
ESMO Open10.1016/j.esmoop.2020.100014202161100014ESMO20 YO for YO: highlights on adjuvant CDK4/6 inhibitors in early hormone receptor-positive/HER2-negative breast cancerA. Matikas, M. Lambertinihttps://api.elsevier.com/content/article/PII:S2059702920328799?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S2059702920328799?httpAccept=text/plain